证券代码：300404 证券简称：博济医药 公告编号：2025-087 博济医药科技股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）近日接到公司控股股东王 廷春先生的通知，获悉王廷春先生将其所持有的公司部分股份在广发证券股份有 限公司（以下简称"广发证券"）办理了股份解除质押的手续，具体事项如下： 一、股东股份解除质押的基本情况 1、本次解除质押基本情况 | 股东名称 | 持股数量 | 持股比例 | 累计质押股 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 持股份 | 总股本 | 已质押股 | 占已质 | 未质押股 | 占未质 | | | | | 份数量 | 比例 | 比例 | 份限售和 | 押股份 | 份限售和 | 押股份 | | | | | | | | 冻结数量 | 比例 | 冻结数量 | 比 ...

博济医药（300404.SZ）12月17日在投资者互动平台表示，目前公司在美国有成熟的承接中美双报业务 的子公司及团队；成立的美国临床子公司目前也已承接海外临床业务；国内组建了海外业务部门用于承 接国际多中心临床项目；通过引入有国际业务经验的人才，积极拓展国外临床业务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：CRO公司都在出海，公司为何不抓住政策风口，做大 做强？ ...

Group 1 - Xinfang Pharmaceutical is facing prosecution for alleged corporate bribery, which may negatively impact its brand reputation, business expansion, and future development [1] - The case is currently in the review and prosecution stage, with the final outcome dependent on legal documents issued by judicial authorities [1] Group 2 - Boji Pharmaceutical's actual controller Wang Tingchun and his concerted parties have collectively reduced their stake in the company by 2.98%, amounting to approximately 11.49 million shares [2] - The share reduction was executed through block trading and centralized bidding, and it is part of a compliant plan that does not alter the company's control [2] - This reduction is likely aimed at optimizing asset allocation, which may temporarily affect investor sentiment [2] Group 3 - Yifang Biotechnology has announced plans to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness [3] - The company is currently in discussions with relevant intermediaries regarding the details of the issuance and listing, which have not yet been finalized [3] - The A+H share strategy is expected to broaden international financing channels and support the development of innovative drugs in oncology and other fields [3]

2025 年 10 月 18 日，公司在巨潮资讯网（www.cninfo.com.cn）上披露了《关 于控股股东及其一致行动人减持股份进展暨权益变动触及 1%的公告》（公告编号： 2025-078），费米十三号在 2025 年 9 月 12 日至 2025 年 10 月 17 日期间，通过集 中竞价合计减持公司股票 1,161,000 股，占公司总股本的 0.30%（占公司剔除回 1 购专用证券账户中股份数量后总股本的 0.30%）。本次权益变动后，公司控股股 东、实际控制人王廷春先生及其一致行动人赵伶俐女士、费米十三号合计持有公 司股份 142,269,690 股，占公司总股本的 36.88%（占公司剔除回购专用证券账户 中股份数量后总股本的 37.14%）。 证券代码：300404 证券简称：博济医药 公告编号：2025-086 博济医药科技股份有限公司 关于控股股东及其一致行动人减持计划实施完毕的公告 公司控股股东王廷春先生及其一致行动人赵伶俐、横琴广金美好基金管理有 限公司－广金美好费米十三号私募证券投资基金保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董 ...

证券日报网讯12月9日，博济医药（300404）在互动平台回答投资者提问时表示，公司中药研发业务稳 步增长，中药创新药自研项目进展顺利。其中，用于治疗膝骨关节炎的中药1.1类品种"卿芷软膏"获得 药物临床试验批准通知书。 ...

证券日报网讯12月9日，博济医药（300404）在互动平台回答投资者提问时表示，为遵循公平原则，保 护全体股东的合法权益，公司暂不在互动平台上披露公司股东人数信息，敬请谅解。 ...

Group 1 - The core viewpoint is that innovative drug commercial insurance is expected to alleviate the medication burden on patients and open new market channels for pharmaceutical companies, thereby enhancing confidence in R&D for innovative drugs within the industry [1] - The company, as a specialized CRO service provider, is likely to gain more new drug R&D projects and orders [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-12-09 | 300404 | 博济医药 | 8.87 | 66.00 | 585.42 西南证券股份有限 | 广发证券股份有限 | | | | | | | 公司山西分公司 | 公司广州天河路证 | | | | | | | | 劳营业部 | | 2025-12-09 | 300404 | 博济医药 | 8.87 | 106.07 | 940.84 西南证券股份有限 | 华泰证券股份有限 | | | | | | | 公司山西分公司 | 公司广州琶洲大道 | | | | | | | | 证券量非部 | 12月9日，博济医药大宗交易成交172.07万股，成交额1526.26万元，占当日总成交额的27.87%，成交价 8.87元，较市场收盘价9.62元折价7.8%。 ...

证券日报网讯12月9日晚间，博济医药（300404）发布公告称，公司获得国家知识产权局颁发的发明专 利证书，发明名称为"一种双氯芬酸钠药物制剂及其制备方法和应用"，专利号ZL202510581633.4，授权 公告日2025年12月5日。公司表示，该专利有利于技术创新，完善知识产权保护体系，提升核心竞争 力。 ...

Core Insights - The single License-out transaction amount has surpassed $3 billion, and the total overseas transaction amount for the year is approaching $100 billion, indicating that Chinese innovative drugs have quietly entered the "hard currency" era [1][3] - This surge in transaction volume signals a systematic rise of the Chinese pharmaceutical industry within the global value chain, driven by qualitative changes in R&D capabilities and strategic vision [1][3] Industry Challenges - Key questions need to be clarified amidst the excitement: Is the explosion of transactions an偶然 or a必然? What are the deep drivers behind the $92.03 billion figure? [2][4] - How can leading companies transition from "selling rights" to "co-creating"? [2][4] - How can small and medium-sized pharmaceutical companies avoid the red ocean and find their own "small but beautiful" pathways for overseas expansion? [2][4] - In the face of valuation bubbles and negotiation games, how can companies scientifically grasp the timing of licensing and anchor fair prices? [2][4] Event Announcement - On December 17, a live session titled "New Drug Relativity" will be co-hosted by Yaoduo and Boji Pharmaceutical, addressing these core issues with industry experts [2][4][5] - The session will feature Wan Jin, founding partner of Yuanjin Venture Capital, James Li, Vice President of Business Development at BIOTrialMed, and Ding Hongxia, co-founder of Yaoduo, to explore the core dynamics and future directions of the globalization of Chinese innovative drug value [2][4][5] Company Overview - Yaoduo is a "drug research and development intelligent innovation service platform" driven by big data and deep intelligence interpretation [3][5] - Since its establishment, Yaoduo has focused on integrating advanced IT technologies such as big data, knowledge graphs, and artificial intelligence with pharmaceutical professional knowledge, building a robust pharmaceutical big data collection system [3][5] - With over 10 years of accumulation, Yaoduo possesses a vast data lake/warehouse (500TB) and has developed unique algorithms for deep trend prediction and opportunity recommendation, empowering decision-making and innovation in the pharmaceutical industry [3][5]